Economic evaluation is becoming increasingly important in the health technology appraisal of innovations in oncology, requiring accurate costing estimations.
The objective of the MELISSA study was to estimate in France the mean cost per patient-year of:
• Hospitalizations related to melanoma in the advanced/metastatic setting in pre and post progression health states.
• Chemotherapies/immunotherapies scheduled administration, i.e. fotemustine and ipilimumab.
• Clinical events presumably related to melanoma immunotherapy and BRAF targeted treatments.
• Palliative care.
• Transportation.
These estimated hospital costs will be useful to populate cost-effectiveness models.
BACKGROUND AND AIMS

Characteristics of patients and stays
Among 78,750 stays which were identified with the combination of C43* AND (C77* or C78* or C79*) ICD-10 codes within PMSI MCO in 2011 MCO in , 2012 MCO in and 2013 were considered as directly related to melanoma, corresponding to 9,843 adult patients. 8,862 of them were classified as naive. Some of these 8,862 patients were also hospitalized in SSR and/or HAD after one of their MCO stays. The final selection was therefore 63,268 stays in 8,862 patients (Fig. 2) .
Mean cost per patient-year (using adjusted-ENCC)
Estimate of mean cost per patient-year of hospitalizations for metastatic melanoma after correction were: in the pre-progression state €4,973 and €32,320 in the post-progression state (Fig. 3) .
Similarly, costs were higher in the post-progression health state for clinical events (€8,827 vs €4,177) and for transportation (€2,536 vs €619). On the contrary, they were higher in the pre-progression state for administration of chemotherapies/immunotherapies (€23,047 vs €17,884). For palliative care, post-progression health state mean cost per patient-year was €19,894.
Hospitalizations with chemotherapies/immunotherapies: 3 types of valuations
The mean cost per administration of ipilimumab, of fotemustine and of chemotherapies, whichever progression state, was estimated according to the 3 types of valuations (ENCC, Adjusted-ENCC and T2A).
For ipilimumab, the mean total cost (drug + stay associated to its administration) was less than €1,000 with ENCC, whereas it reached €16,000 with adjusted-ENCC and T2A valuations (Fig. 4) .
The mean cost of administration of fotemustine was around €900 (drug + stay associated to its administration) whichever valuations (Fig. 5 ).
For chemotherapies, the mean total cost with ENCC was around €1,000, whereas it went beyond €500 with adjusted-ENCC and T2A (Fig.6) .
Using adjusted-ENCC valuation only, when considering a drug from the expensive drug list and funded in addition to DRGs, the mean cost included:
• The administration of the drug (stay): €400-450; • The drug itself: €16,000 for ipilimumab and €450 for fotemustine.
For a drug covered by the DRG, this mean cost per administration was around €530, including both the administration and the drug costs (Fig. 7) .
RESULTS
Data extraction
Study period: January 1st, 2011 to December 31st, 2013. 
Patients and hospital stays selection
Incident adult patients hospitalized with the following criteria were included:
• Malignant melanoma of skin (ICD-10 code C43*) as PD/RD/SAD (Principal Diagnosis / Related Diagnosis / Significantly Associated Diagnosis).
• And at least one metastasis ICD-10 code C77* ("Secondary and unspecified malignant neoplasm of lymph nodes"), C78* ("Secondary malignant neoplasm of respiratory and digestive organs") or C79* ("Secondary malignant neoplasm of other and unspecified sites") as PD/RD/SAD.
• No chemotherapy session within 2 years prior to inclusion (naive patient).
The following stays or patients were excluded:
• Presence of another code of primary tumor, since it was not possible to determine whether the metastasis was due to melanoma or to the other primary tumor, unless:
• Ipilimumab was administered, • Fotemustine was administered in absence of malignant cerebral tumor (ICD-10 code C71*).
• Hospital stays not related to melanoma, based on ICD-10 codes algorithm previously set up with experts.
Classification into progression health states
All selected stays were assigned into 2 sub-groups: either pre-progression or post-progression defined by the RECIST (Response Evaluation Criteria In Solid Tumors) 1.1 criteria 1 , which could be translated into PMSI characteristics as follows:
• The occurrence of any new metastasis which was not present at inclusion.
• Cerebral metastases and palliative care always classified as post-progression state.
• Any treatment change.
Valuation
• Valuation of the stays was done through the French official tariffs (T2A, Tarification À l'Activité), the hospital production costs (ENCC, Étude Nationale de Coûts à méthodologie Commune -French National Cost Study) and the adjusted-ENCC (in order to take into account expensive drugs administered in our cohort only).
• Valuation of transportation costs was done through the official tariffs according to 2 assumptions:
• 100% of patients used reimbursed transportation to come to and to leave hospital.
• Different means of transportation distributed as for the general population.
Calculation of duration in each progression health states
For each patient and for each state, cumulative time in days was calculated, as stated in Fig. 1 .
Calculation of the mean annual cost per patient per progression health state
Costs associated to hospital stays in each progression health state were added up and a mean annual cost per patient estimated, according to the following formula:
Mean cost per patient year per progression health state
Correction of the mean annual cost
As only inpatient deaths are captured into the PMSI, estimated outpatient deaths were imputed, based on published literature Adjusted-ENCC and T2A valuations both show that the mean cost of ipilimumab (€15,965) represented around 35 times the mean cost of its administration (€424 -454). The ENCC valuation does not reflect this difference. Costs included in the ENCC item "expensive drugs" are not limited to ipilimumab costs but also cover several other drugs. Ipilimumab costs are therefore leveraged by costs associated to other drugs, which are potentially less expensive. Using an adjusted-ENCC valuation seems to be the best way to reflect real practices. Adjusted-ENCC seems therefore to be the optimal valuation method to be used when the cost of a drug from the expensive drug list administration has to be estimated. In addition, it also seems to be the optimal method to be used when the cost of drugs included inside DRGs has to be estimated.
The PMSI represents a comprehensive collection of all inpatient stays in France, intended to analyze hospital activity. However, it also allows economic research with some limitations to be considered: neither all clinical characteristics are gathered (size of metastases), nor outpatient costs (treatment, outpatient visits, sick leave…); SSR ENCC costs cannot be estimated.
Deaths occurring outside of the hospital are not caught in the PMSI database; however, this was taken into account through a correction of the follow-up period.
The transportation distribution was based on the general population; in addition, all stays were assumed to be linked to a transportation reimbursed by the National Health Insurance. Even if it might over-estimate the total amount of transportation costs, it allows a first estimate of transportation costs in France for metastatic melanoma.
The MELISSA study is the first estimation of hospital costs specifically associated with advanced melanoma in France in the new era of immunotherapies. It will be useful as an updated reference for costing estimations within health economics analyses conducted in this disease.
